Savara

News

Savara shares are pummelled after the FDA says it cannot accept a filing for lead drug Molbreevi, but it is still hopeful of an approval in 2026.

News

Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.